Provided by Tiger Trade Technology Pte. Ltd.

CHINARES PHARMA

4.550
-0.040-0.87%
Volume:10.58M
Turnover:48.38M
Market Cap:28.59B
PE:8.58
High:4.610
Open:4.560
Low:4.530
Close:4.590
52wk High:5.668
52wk Low:4.340
Shares:6.28B
HK Float Shares:6.28B
Volume Ratio:0.82
T/O Rate:0.17%
Dividend:0.14
Dividend Rate:3.09%
EPS(LYR):0.530
ROE:7.57%
ROA:2.66%
PB:0.50
PE(LYR):8.58
PS:0.10

Loading ...

KPC Pharmaceutical's 2025 Profit Slips 46%

MT Newswires Live
·
Feb 06

Tasly Pharmaceutical Reports 11.05 Billion Yuan Net Profit for 2025, Marking 15.68% Year-on-Year Growth

Stock News
·
Feb 06

CR Pharmaceutical (3320) Announces CR Sanjiu’s 2025 Preliminary Financial Results

Bulletin Express
·
Feb 06

CR Sanjiu Posts 14.53% Revenue Growth Under China Resources Pharmaceutical Group

Reuters
·
Feb 06

CR Sanjiu steigert Umsatz um 14,53 Prozent und bleibt Tochtergesellschaft der China Resources Pharmaceutical Group

Reuters
·
Feb 06

Tasly Pharmaceutical Affiliate Posts Preliminary 2025 Results Under China Resources Pharmaceutical Group

Reuters
·
Feb 06

Tasly Pharmaceutical meldet vorläufige Jahreszahlen 2025 als assoziiertes Unternehmen von China Resources Pharmaceutical Group

Reuters
·
Feb 06

China Resources Pharmaceutical (3320) Releases KPC’s 2025 Preliminary Financial Results

Bulletin Express
·
Feb 06

China Resources Pharmaceutical Group Ltd - FY Prelim Net Profit Attributable for Kpc Pharmaceuticals RMB349.9 Mln

THOMSON REUTERS
·
Feb 06

China Resources Pharmaceutical Group Ltd. meldet Gewinnrückgang bei assoziiertem Unternehmen KPC Pharmaceuticals

Reuters
·
Feb 06

China Resources Pharmaceutical Group (03320) Announces January 2026 Share Movements

Bulletin Express
·
Feb 02

HK Stock Movement | CHINARES PHARMA (03320) Falls Nearly 3%; China Resources Boya Bio-Pharmaceutical Anticipates Significant Annual Net Profit Decline

Stock News
·
Feb 02

China Resources Pharma (03320): Boya Bio Anticipates Annual Net Profit of 105-136.5 Million Yuan, Marking Significant Year-on-Year Decline

Stock News
·
Jan 30

China Resources Pharmaceutical Sees Net Profit Attributable of Cr Boya Bio-Pharmaceutical for Year From RMB105.00 Mln to RMB136.50 Mln

THOMSON REUTERS
·
Jan 30

China Resources Pharmaceutical - Cr Boya Bio-Pharmaceutical Expected to Achieve Increase of 10% to 25% in Operating Revenue in FY

THOMSON REUTERS
·
Jan 30

CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn

Reuters
·
Jan 30

Immunotech Biopharm Signs Cell Therapy Processing Agreement with Tasly

Reuters
·
Jan 27

Take Care Before Diving Into The Deep End On China Resources Pharmaceutical Group Limited (HKG:3320)

Simply Wall St.
·
Jan 27

BRIEF-China Resources Pharmaceutical Receives Notice Of Registration Approval Issued By China Securities Regulatory Commission

Reuters
·
Jan 27

CHINARES PHARMA (03320) Subsidiary China Resources Double-Crane Gets Approval to Issue RMB 3 Billion Corporate Bonds

Stock News
·
Jan 26